Cargando…

SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19

Although coronavirus disease 2019 (COVID-19) causes cardiac dysfunction in up to 25% of patients, its pathogenesis remains unclear. Exposure of human induced pluripotent stem cell (iPSC)-derived heart cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed productive infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Bermejo, Juan A., Kang, Serah, Rockwood, Sarah J., Simoneau, Camille R., Joy, David A., Silva, Ana C., Ramadoss, Gokul N., Flanigan, Will R., Fozouni, Parinaz, Li, Huihui, Chen, Pei-Yi, Nakamura, Ken, Whitman, Jeffrey D., Hanson, Paul J., McManus, Bruce M., Ott, Melanie, Conklin, Bruce R., McDevitt, Todd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128284/
https://www.ncbi.nlm.nih.gov/pubmed/33723017
http://dx.doi.org/10.1126/scitranslmed.abf7872
Descripción
Sumario:Although coronavirus disease 2019 (COVID-19) causes cardiac dysfunction in up to 25% of patients, its pathogenesis remains unclear. Exposure of human induced pluripotent stem cell (iPSC)-derived heart cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed productive infection and robust transcriptomic and morphological signatures of damage, particularly in cardiomyocytes. Transcriptomic disruption of structural genes corroborates adverse morphologic features, which included a distinct pattern of myofibrillar fragmentation and nuclear disruption. Human autopsy specimens from patients with COVID-19 reflected similar alterations, particularly sarcomeric fragmentation. These striking cytopathic features in cardiomyocytes provide insights into SARS-CoV-2-induced cardiac damage, offer a platform for discovery of potential therapeutics, and raise concerns about the long-term consequences of COVID-19 in asymptomatic as well as severe cases.